Please login to the form below

Not currently logged in
Email:
Password:

Market wants asthma delivery options

The differentiation of new asthma therapies is becoming increasingly challenging, though a new report suggests that the future market will respond positively to means of drug delivery which offer flexibility and choice for patients.

The differentiation of new asthma therapies is becoming increasingly challenging, though a new report suggests that the future market will respond positively to means of drug delivery which offer flexibility and choice for patients.

Combination products for asthma are also growing in popularity, according to research undertaken for a new report, Asthma: Novel Product Differentiation Remains a Key Challenge, produced by international healthcare research and advisory firm, Decision Resources.

"Pulmologists emphasise that delivery device and formulation can influence patient compliance and, in turn, outcomes - as a result, they value a variety of options for their patients,"noted Dr Cindy Mundy, director at the company.

The report spotlights the new formoterol/mometasone bronchodilator combination product in development by Schering-Plough and Novartis, anticipated to gain marketing approval next year. According to the findings, S-P and Novartis may have similar flexibility in terms of delivery options for formoterol/mometasone as does the current market leader, GlaxoSmithKline, for Seretide

The report predicts, however, that 'following its approval, Schering-Plough/Novartis' formoterol/mometasone will become the clinical gold standard for asthma by 2011, owing to its competitive advantages in delivery', adding too that 'urveyed primary care physicians indicated they word prescribe formoterol/mometasone to 34 per cent of their patients with persistent asthma'.

Decision Resources compiles it reports by combining market forecasts with clinical and commercial endpoints. Its market share projections also rely on feedback elicited through prescriber surveys.

Some positive editorial coverage and opinion have been given over to the new combination offering, which could be made available in both dry power inhaler and metered dose inhaler formulations, however the product's two developers have not yet confirmed on plans for its method of administration.

28th January 2008

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Life Healthcare Communications

Life is a creative communications agency offering multi-channel solutions for the healthcare industry. We use a storytelling approach to turn...

Latest intelligence

Island
Pharma’s isolated islands of innovation
With service design and technology often failing the patient, why perspective on improving outcomes need to change...
Uncertainty, austerity and Brexit
What does it mean for the life science sector?...
The Holy Grail of HCP Access
This is the data you need to gain access....

Infographics